Cu-67 SAR-Bombesin

**Cu-67 SAR-Bombesin** is a targeted copper theranostic radiopharmaceutical developed by Clarity Pharmaceuticals for treating gastrin-releasing peptide receptor (GRPr)-expressing cancers, particularly in patients ineligible for PSMA-targeted therapies. It consists of a bombesin antagonist peptide conjugated to Clarity's proprietary sarcophagine (SAR) chelator, which securely binds copper-67 (67Cu), a beta-emitting isotope with a 2.6-day half-life suitable for therapy. The agent delivers targeted radiation to GRPr-positive tumor cells, achieving 93.3% tumor growth inhibition in preclinical PC-3 prostate cancer models with minimal toxicity and rapid clearance from non-target organs via renal and hepatobiliary pathways. It is being evaluated in the Phase I/II COMBAT trial (NCT05633160) for metastatic castrate-resistant prostate cancer (mCRPC), with doses up to 14 GBq planned in up to four cycles following 64Cu-SAR-Bombesin imaging for patient selection.[1][3][5]

Other names

67Cu SAR-Bombesin